Baxter International Inc. has agreed to sell its kidney care business unit to global investment firm Carlyle for $3.8b, the companies announced on 13 August.
The business will be known as Vantive.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?